Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 249Rectal Neoplasms 154Pancreatic Neoplasms 125Stomach Neoplasms 105Colonic Neoplasms 104Esophageal Neoplasms 90Neoplasm Metastasis 69Breast Neoplasms 61Squamous Cell Carcinoma of Head and Neck 47Carcinoma, Hepatocellular 42Adenocarcinoma Of Esophagus 41Head and Neck Neoplasms 39Esophageal Squamous Cell Carcinoma 38Neoplasms 37Nasopharyngeal Carcinoma 30Adenocarcinoma 24Cholangiocarcinoma 20Keratosis, Actinic 17Carcinoma, Squamous Cell 16Biliary Tract Neoplasms 16Liver Neoplasms 15Gastrointestinal Neoplasms 15Anus Neoplasms 14Gallbladder Neoplasms 11Bile Duct Neoplasms 11Peritoneal Neoplasms 10Laryngeal Neoplasms 9Recurrence 8Nasopharyngeal Neoplasms 7Colorectal Cancer Metastatic 7

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Efficacy and Safety × Fluorouracil × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡